Memantine
Product Images NDC 0615-8100

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine (NDC 0615-8100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine HCl Tablets 5mg 10mg 1

Chemical structure of memantine hydrochloride, showing the molecular arrangement with amino and methyl groups attached to a bicyclo compound.*

FDA Label Image

Memantine HCl Tablets 5mg 10mg 10

Label for Memantine HCl Tabs USP 10 mg, with a quantity of 30 tablets. The label indicates the product is manufactured by Dr. Reddy's and packaged by Vanguard Labs in Glasgow, KY. The label includes barcodes, lot number 8100, storage instructions at 20°-25°C, and a note for institutional use only.*

FDA Label Image

Memantine HCl Tablets 5mg 10mg 11

Label for Memantine HCl Tablets USP 5 mg, manufactured by Dr. Reddy's and packaged by NCS HealthCare of KY, LLC dba Vangard Labs in Glasgow, KY. The label includes lot number 8192, quantity of 30 tablets, barcode, storage instructions at controlled room temperature, and designated for institutional use only.*

FDA Label Image

Memantine HCl Tablets 5mg 10mg 2

A line graph comparing the mean change from baseline in ADCS-ADL score over 28 weeks of treatment for Memantine HCl and placebo. The x-axis shows weeks of treatment (0, 4, 12, 28), and the y-axis shows mean ± SEM change scores, with lines depicting clinical improvement and decline. Memantine HCl shows less decline over time compared to placebo.*

FDA Label Image

Memantine HCl Tablets 5mg 10mg 3

A line graph comparing the cumulative percentage of patients between placebo and Memantine HCl groups. The x-axis represents ADCS-ADL change from baseline, while the y-axis shows cumulative percentage of patients. Two curves illustrate differences in patient response over a range of ADCS-ADL score changes.*

FDA Label Image

Memantine HCl Tablets 5mg 10mg 4

A line graph depicting mean change from baseline in SIB (Severe Impairment Battery) score over weeks of treatment with Memantine HCl compared to placebo. The x-axis shows weeks of treatment up to 28 weeks, and the y-axis shows mean change in SIB score with indicators for clinical improvement and clinical decline. Error bars represent SEM.*

FDA Label Image

Memantine HCl Tablets 5mg 10mg 5

A line graph showing cumulative percentage of patients over SIB change from baseline comparing Placebo and Memantine HCl groups. The x-axis represents SIB change from baseline, and the y-axis represents cumulative percentage of patients. Two lines track patient percentages across SIB changes for each group.*

FDA Label Image

Memantine HCl Tablets 5mg 10mg 6

A line graph showing the mean change in ADAS-Cog scores from baseline over 24 weeks of treatment. The x-axis represents weeks of treatment from 0 to 24, and the y-axis shows the mean change in scores, with markers for clinical improvement and clinical decline. Two treatment groups are compared: Placebo/Donepezil and Memantine HCl/Donepezil, with the graph indicating difference trends over time.*

FDA Label Image

Memantine HCl Tablets 5mg 10mg 7

A cumulative percentage of patients graph showing ADCS-ADL change from baseline. It compares two lines labeled 'Placebo/Donepezil' and 'Memantine HCl/Donepezil,' displaying patient response distributions over changes in ADCS-ADL scores.*

FDA Label Image

Memantine HCl Tablets 5mg 10mg 8

A line graph depicting mean change from baseline in standard error of the mean (SEM) ADAS-cog scores over 24 weeks of treatment. Two groups are compared: one receiving Placebo/Donepezil and the other Memantine HCl/Donepezil. The graph shows clinical improvement above the baseline line and clinical decline below it, with error bars indicated for data points.*

FDA Label Image

Memantine HCl Tablets 5mg 10mg 9

A cumulative percentage of patients versus SIB (Severe Impairment Battery) change from baseline plot comparing Placebo/Donepezil and Memantine HCl/Donepezil groups. The graph shows the response trends of these treatments over a change range from positive to negative values.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.